Gastric Cancer: An Infectious Disease

Infectious Disease Clinics of North America

Volumn 24, Issue 4, 2010, Pages 853-869

  Piazuelo, M Blanca ^a   Epplein, Meira ^a   Correa, Pelayo ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Gastric adenocarcinoma; Gastric cancer; Helicobacter pylori

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

BACTERIAL VIRULENCE; BACTERIUM DETECTION; CANCER CLASSIFICATION; CANCER CONTROL; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ETHNICITY; FEEDING BEHAVIOR; GENETIC POLYMORPHISM; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; NONHUMAN; PRECANCER; REVIEW; RISK REDUCTION; SMOKING HABIT; SOCIAL STATUS; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS;

ADENOCARCINOMA; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; STOMACH NEOPLASMS; WORLD HEALTH;

EID: 77957737900     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.07.010     Document Type: Review

References (108)

1. IARC Monographs on the evaluation of carcinogenic risks to humans Schistosomes, liver flukes and Helicobacter pylori 1994, International Agency for Research on Cancer, Lyon (France), p. 177-240.
2. Honda S., Fujioka T., Tokieda M., et al. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res 1998, 58(19):4255-4259.
3. Bouvard V., Baan R., Straif K., et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009, 10(4):321-322.
4. Coleman M.P., Esteve J., Damiecki P., et al. Trends in cancer incidence and mortality 1993, International Agency for Research on Cancer, Lyon (France).
5. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
6. Thun M.J., DeLancey J.O., Center M.M., et al. The global burden of cancer: priorities for prevention. Carcinogenesis 2010, 31(1):100-110.
7. Espey D.K., Wu X.C., Swan J., et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007, 110(10):2119-2152.
8. Wu X., Chen V.W., Andrews P.A., et al. Incidence of esophageal and gastric cancers among hispanics, non-hispanic whites and non-hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 2007, 18(6):585-593.
9. Wu X., Chen V.W., Ruiz B., et al. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer 2006, 106(3):683-692.
10. Anderson W.F., Camargo M.C., Fraumeni J.F., et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010, 303(17):1723-1728.
11. Helicobacter and Cancer Collaborative Group Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49(3):347-353.
12. Kamangar F., Dawsey S.M., Blaser M.J., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98(20):1445-1452.
13. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345(11):784-789.
14. Leavell H.R., Clark E.G. Preventive medicine for the doctor in his community; an epidemiologic approach 1965, McGraw-Hill, New York.
15. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968, 40(1):43-68.
16. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1(8390):1311-1315.
17. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118(12):3030-3044.
18. Cover T.L., Blaser M.J. Helicobacter pylori in health and disease. Gastroenterology 2009, 136(6):1863-1873.
19. Peek R.M., Crabtree J.E. Helicobacter infection and gastric neoplasia. J Pathol 2006, 208(2):233-248.
20. Achtman M., Azuma T., Berg D.E., et al. Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol Microbiol 1999, 32(3):459-470.
21. Falush D., Wirth T., Linz B., et al. Traces of human migrations in Helicobacter pylori populations. Science 2003, 299(5612):1582-1585.
22. Linz B., Balloux F., Moodley Y., et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007, 445(7130):915-918.
23. Censini S., Lange C., Xiang Z., et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996, 93(25):14648-14653.
24. Covacci A., Censini S., Bugnoli M., et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993, 90(12):5791-5795.
25. Devi S.M., Ahmed I., Khan A.A., et al. Genomes of Helicobacter pylori from native Peruvians suggest admixture of ancestral and modern lineages and reveal a western type cag-pathogenicity island. BMC Genomics 2006, 7:191.
26. Dominguez-Bello M.G., Perez M.E., Bortolini M.C., et al. Amerindian Helicobacter pylori strains go extinct, as European strains expand their host range. PLoS One 2008, 3(10). e3307.
27. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009, 44(4):239-248.
28. Tham K.T., Peek R.M., Atherton J.C., et al. Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. Hum Pathol 2001, 32(3):264-273.
29. Blaser M.J., Perez-Perez G.I., Kleanthous H., et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995, 55(10):2111-2115.
30. Parsonnet J., Friedman G.D., Orentreich N., et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 40(3):297-301.
31. Plummer M., van Doorn L.J., Franceschi S., et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst 2007, 99(17):1328-1334.
32. Bravo L.E., van Doom L.J., Realpe J.L., et al. Virulence-associated genotypes of Helicobacter pylori: do they explain the African enigma?. Am J Gastroenterol 2002, 97(11):2839-2842.
33. Cover T.L., Blanke S.R. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 2005, 3(4):320-332.
34. Hansson L.E., Nyren O., Hsing A.W., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996, 335(4):242-249.
35. Murphy G., Pfeiffer R., Camargo M.C., et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009, 137(3):824-833.
36. Akiba S., Koriyama C., Herrera-Goepfert R., et al. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci 2008, 99(2):195-201.
37. World Cancer Research Fund/American Institute for Cancer Research Food, nutrition, physical activity, and the prevention of cancer: a global perspective 2007, AICR, Washington, DC.
38. Fox J.G., Dangler C.A., Taylor N.S., et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999, 59(19):4823-4828.
39. Yamaguchi N., Kakizoe T. Synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer. Lancet Oncol 2001, 2(2):88-94.
40. Epplein M., Nomura A.M., Hankin J.H., et al. Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case-control study in Hawaii. Cancer Causes Control 2008, 19(8):869-877.
41. Gonzalez C.A., Pera G., Agudo A., et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 2006, 118(10):2559-2566.
42. Secretan B., Straif K., Baan R., et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009, 10(11):1033-1034.
43. Ladeiras-Lopes R., Pereira A.K., Nogueira A., et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008, 19(7):689-701.
44. IARC Monographs on the evaluation of carcinogenic risks to humans Tobacco smoke and involuntary smoking 2004, International Agency for Research on Cancer, Lyon (France), p. 59-94.
45. Gonzalez C.A., Pera G., Agudo A., et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003, 107(4):629-634.
46. Abnet C.C., Freedman N.D., Kamangar F., et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009, 100(3):551-557.
47. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94(4):252-266.
48. Baron J.A. Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res 2009, 181:223-229.
49. Leung W.K., Ng E.K., Chan F.K., et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006, 12(15):4766-4772.
50. Cuzick J., Otto F., Baron J.A., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10(5):501-507.
51. Nyren O., Adami H.-O. Stomach cancer. Textbook of cancer epidemiology 2002, 162-187. Oxford University Press, New York. H.-O. Adami, D. Hunter, D. Trichopoulos (Eds.).
52. Nomura A. Stomach cancer. Cancer epidemiology and prevention 1996, 707-724. Oxford University Press, New York. 2nd edition. D. Schottenfeld, J. Fraumeni (Eds.).
53. Nguyen L.T., Uchida T., Murakami K., et al. Helicobacter pylori virulence and the diversity of gastric cancer in Asia. J Med Microbiol 2008, 57(Pt 12):1445-1453.
54. Holcombe C. Helicobacter pylori: the African enigma. Gut 1992, 33(4):429-431.
55. Segal I., Ally R., Mitchell H. Gastric cancer in sub-Saharan Africa. Eur J Cancer Prev 2001, 10(6):479-482.
56. Correa P., Cuello C., Duque E., et al. Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst 1976, 57(5):1027-1035.
57. Camargo M.C., Yepez M.C., Ceron C., et al. Age at acquisition of Helicobacter pylori infection: comparison of two areas with contrasting risk of gastric cancer. Helicobacter 2004, 9(3):262-270.
58. Tsuji S. The " Costa Rican enigma" of Helicobacter pylori CagA and gastric cancer. J Gastroenterol 2006, 41(7):716-717.
59. Con S.A., Valerin A.L., Takeuchi H., et al. Helicobacter pylori CagA status associated with gastric cancer incidence rate variability in Costa Rican regions. J Gastroenterol 2006, 41(7):632-637.
60. Sicinschi L.A., Correa P., Peek R.M., et al. Helicobacter pylori genotyping and sequencing using paraffin-embedded biopsies from residents of Colombian areas with contrasting gastric cancer risks. Helicobacter 2008, 13(2):135-145.
61. Mitchell H.M., Ally R., Wadee A., et al. Major differences in the IgG subclass response to Helicobacter pylori in the first and third worlds. Scand J Gastroenterol 2002, 37(5):517-522.
62. Whary M.T., Sundina N., Bravo L.E., et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev 2005, 14(6):1464-1469.
63. Piazuelo M.B., Camargo M.C., Mera R.M., et al. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol 2008, 39(9):1360-1369.
64. Fox J.G., Beck P., Dangler C.A., et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000, 6(5):536-542.
65. Du Y., Agnew A., Ye X.P., et al. Helicobacter pylori and Schistosoma japonicum co-infection in a Chinese population: helminth infection alters humoral responses to H. pylori and serum pepsinogen I/II ratio. Microbes Infect 2006, 8(1):52-60.
66. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404(6776):398-402.
67. El-Omar E.M., Carrington M., Chow W.H., et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001, 412(6842):99. [erratum].
68. El-Omar E.M. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001, 48(6):743-747.
69. Camargo M.C., Mera R., Correa P., et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(9):1674-1687.
70. El-Omar E.M., Rabkin C.S., Gammon M.D., et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124(5):1193-1201.
71. Gorouhi F., Islami F., Bahrami H., et al. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008, 98(8):1443-1451.
72. Machado J.C., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125(2):364-371.
73. Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002, 94(22):1680-1687.
74. Sicinschi L.A., Lopez-Carrillo L., Camargo M.C., et al. Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and -10 genes. Int J Cancer 2006, 118(3):649-657.
75. Correa P., Camargo M.C., Piazuelo M.B. Overview and pathology of gastric cancer. The biology of gastric cancers 2009, 1-24. Springer, New York. T.C. Wang, J.G. Fox, A.S. Giraud (Eds.).
76. Brown L.M., Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002, 11(2):235-256.
77. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265(10):1287-1289.
78. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83(10):2049-2053.
79. Devesa S.S., Fraumeni J.F. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999, 91(9):747-749.
80. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85(11):1457-1459.
81. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer 1998, 1(1):10-24.
82. Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965, 64:31-49.
83. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52(24):6735-6740.
84. Correa P., Haenszel W., Cuello C., et al. A model for gastric cancer epidemiology. Lancet 1975, 2(7924):58-60.
85. Correa P., Bolanos O., Garcia F., et al. The cancer registry of Cali, Colombia. Epidemiologic studies of gastric cancer. Recent Results Cancer Res 1975, 50:155-169.
86. Correa P., Cuello C., Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970, 44(2):297-306.
87. Filipe M.I., Munoz N., Matko I., et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994, 57(3):324-329.
88. Tava F., Luinetti O., Ghigna M.R., et al. Type or extension of intestinal metaplasia and immature/atypical " indefinite-for-dysplasia" lesions as predictors of gastric neoplasia. Hum Pathol 2006, 37(11):1489-1497.
89. Kikuchi S., Wada O., Nakajima T., et al. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 1995, 75(12):2789-2793.
90. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392(6674):402-405.
91. Guilford P.J., Hopkins J.B., Grady W.M., et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14(3):249-255.
92. Lynch H.T., Kaurah P., Wirtzfeld D., et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008, 112(12):2655-2663.
93. Pharoah P.D., Guilford P., Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121(6):1348-1353.
94. Machado J.C., Oliveira C., Carvalho R., et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001, 20(12):1525-1528.
95. Tamura G., Yin J., Wang S., et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000, 92(7):569-573.
96. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
97. Sano T., Katai H., Sasako M., et al. The management of early gastric cancer. Surg Oncol 2000, 9(1):17-22.
98. Leung W.K., Wu M.S., Kakugawa Y., et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008, 9(3):279-287.
99. Mera R., Fontham E.T., Bravo L.E., et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005, 54(11):1536-1540.
100. Fuccio L., Zagari R.M., Eusebi L.H., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 2009, 151(2):121-128.
101. Wu C.Y., Kuo K.N., Wu M.S., et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009, 137(5):1641-1648.
102. Lauwers G.Y., Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. Gastroenterol Clin North Am 2007, 36(4):813-829.
103. Correa P., Piazuelo M.B., Wilson K.T. Pathology of gastric intestinal metaplasia: Clinical implications. Am J Gastroenterol 2010, 105(3):493-498.
104. de Vries A.C., Haringsma J., de Vries R.A., et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 2009, 70(1):18-25.
105. Blaser M.J., Falkow S. What are the consequences of the disappearing human microbiota?. Nat Rev Microbiol 2009, 7(12):887-894.
106. Chen Y., Blaser M.J. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 2007, 167(8):821-827.
107. Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila Pa) 2008, 1(5):329-338.
108. Peek R.M., Blaser M.J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002, 2(1):28-37.